294 related articles for article (PubMed ID: 25755211)
1. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
[TBL] [Abstract][Full Text] [Related]
2. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
Dunsmore KP; Winter SS; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Rabin KR; Zweidler-Mckay PA; Raetz EA; Loh ML; Schultz KR; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2020 Oct; 38(28):3282-3293. PubMed ID: 32813610
[TBL] [Abstract][Full Text] [Related]
3. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
Hayashi RJ; Winter SS; Dunsmore KP; Devidas M; Chen Z; Wood BL; Hermiston ML; Teachey DT; Perkins SL; Miles RR; Raetz EA; Loh ML; Winick NJ; Carroll WL; Hunger SP; Lim MS; Gross TG; Bollard CM
J Clin Oncol; 2020 Sep; 38(26):3062-3070. PubMed ID: 32552472
[TBL] [Abstract][Full Text] [Related]
4. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
Winter SS; Dunsmore KP; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Gaynon PS; Borowitz MJ; Loh ML; Rabin KR; Raetz EA; Zweidler-Mckay PA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2018 Oct; 36(29):2926-2934. PubMed ID: 30138085
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Dunsmore KP; Devidas M; Linda SB; Borowitz MJ; Winick N; Hunger SP; Carroll WL; Camitta BM
J Clin Oncol; 2012 Aug; 30(22):2753-9. PubMed ID: 22734022
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report.
Gossai NP; Devidas M; Chen Z; Wood BL; Zweidler-McKay PA; Rabin KR; Loh ML; Raetz EA; Winick NJ; Burke MJ; Carroll AJ; Esiashvili N; Heerema NA; Carroll WL; Hunger SP; Dunsmore KP; Winter SS; Teachey DT
Blood; 2023 Apr; 141(15):1802-1811. PubMed ID: 36603187
[TBL] [Abstract][Full Text] [Related]
7. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
[TBL] [Abstract][Full Text] [Related]
8. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
[TBL] [Abstract][Full Text] [Related]
10. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
12. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
13. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
[TBL] [Abstract][Full Text] [Related]
14. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
Berg SL; Blaney SM; Devidas M; Lampkin TA; Murgo A; Bernstein M; Billett A; Kurtzberg J; Reaman G; Gaynon P; Whitlock J; Krailo M; Harris MB;
J Clin Oncol; 2005 May; 23(15):3376-82. PubMed ID: 15908649
[TBL] [Abstract][Full Text] [Related]
16. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
[TBL] [Abstract][Full Text] [Related]
17. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
18. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
19. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
[TBL] [Abstract][Full Text] [Related]
20. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
